<DOC>
	<DOCNO>NCT00463489</DOCNO>
	<brief_summary>The primary objective trial evaluate effect addition 2 year , centrally deliver individualize , telephone-based lifestyle intervention focus weight management mail educational intervention Disease Free Survival post-menopausal woman early stage breast cancer ( hormone receptor positive ) , BMI ≥24- &lt; 40 kg/m2 , receive standard letrozole adjuvant therapy .</brief_summary>
	<brief_title>Lifestyle Intervention Study Adjuvant Treatment Early Breast Cancer</brief_title>
	<detailed_description>The primary objective trial evaluate effect addition 2 year , centrally deliver individualize , telephone-based lifestyle intervention focus weight management mail educational intervention Disease Free Survival post-menopausal woman early stage breast cancer ( hormone receptor positive ) , BMI ≥24- &lt; 40 kg/m2 , receive standard letrozole adjuvant therapy . The telephone intervention involve 19 phone call , well mailing participant manual ; woman ask lose 10 % weight reduce caloric fat intake ( 500-1000 kcal/day , 20 % calorie fat ) increase moderate physical activity ( 150-200 minutes/week ) . Secondary outcome include overall survival , distant disease-free survival , weight change , health-related quality life ( HRQOL ) , select non-cancer medical event biologic factor ( notably insulin ) . Approximately 2,150 woman enrol ; follow-up continue target event rate meet ( anticipate 4-6 year completion intervention ) . This sample size provide 80 % power ( type 1 error 0.05 2-tailed ) detect hazard ratio ( HR ) DFS 0.74-0.76 weight loss intervention arm .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Postmenopausal woman diagnosis invasive breast cancer ( T13 , pN02 , M0 ) definitive surgery perform previous 36 month . On adjuvant hormonal therapy letrozole time randomization ( either initial adjuvant hormonal therapy switch tamoxifen hormonal therapy ) . BMI ≥ 24 kg/m2 . Medical , surgical radiation oncologist agree subject participation diet physical activity program . Life expectancy less five year . Selfreported inability walk least 2 block ( pace ) . Insulin require diabetes ( telephone direct diet physical activity change would difficult population without close coordination treat physician ) . Noninsulin require diabetic eligible study . Serious digestive and/or absorptive problem , include inflammatory bowel disease chronic diarrhea preclude adherence study diet . Cardiovascular , respiratory musculoskeletal disease joint problem preclude moderate physical activity . Moderate arthritis preclude physical activity reason ineligibility . Psychiatric disorder condition , opinion investigator , would preclude participation study intervention ( e.g . untreated major depression psychosis , substance abuse , severe personality disorder ) . Patients aromatase inhibitor letrozole study entry . Known recurrence breast cancer ( local , regional distant ) time prior study entry . History malignancy except : adequately treat nonmelanoma skin cancer , curatively treat situ carcinoma cervix , solid tumour curatively treat evidence disease ≥ 5 year . Prior situ cancer breast reason exclusion . Patients fluent either English French ( speak write ) . Patient unwilling unable provide inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>lifestyle intervention</keyword>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
	<keyword>adjuvant</keyword>
	<keyword>letrozole</keyword>
	<keyword>weight loss</keyword>
	<keyword>BMI</keyword>
	<keyword>post-menopausal</keyword>
	<keyword>estrogen receptor positive</keyword>
	<keyword>progesterone receptor positive</keyword>
</DOC>